Role of amphotericin B upon enhancement of protective immunity elicited by oral administration with liposome-encapsulated-Japanese encephalitis virus nonstructural protein 1 (NS1) in mice

Lin, Tsung-Shun; Chuang, Chuan-Chang; Hsü, H. F.; Liu, Yu-Tien; Lin, Wei‐Chun; Liang, Chung-Chih; Liu, Wen-Tssann

doi:10.1016/j.micpath.2010.04.002

Cited by 9 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the activation of mucosal immunity plays an important role against JEV transmission. Accumulating data has emerged to develop oral vaccines against JEV and demonstrate the effectiveness of mucosal vaccination approach for JEV vaccine, particularly in the presence of the adjuvant [28,[45][46][47][48][49][50][51][52]. Most of the flaviviruses are arboviruses that transmit mainly through ticks or mosquito bites.…”

Section: Discussionmentioning

confidence: 99%

Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with E. coli heat labile enterotoxin B subunit

et al. 2021

View full text Add to dashboard Cite

Background: Current vaccines against Japanese encephalitis virus (JEV) of flaviviruses have some disadvantages, such as the risk of virulent reversion. Non-structural protein NS1 is conserved among flaviviruses and confers immune protection without the risk of antibody-dependent enhancement (ADE). Therefore, NS1 has become a promising vaccine candidate against flaviviruses. Methods: A NS1-based vaccine (LTB-NS1 Δ63 ) with a truncated NS1 protein (NS1 Δ63 ) fused to E. coli heat-labile enterotoxin B subunit (LTB) was expressed in E.coli and explored for its ability to induce immune responses. Safety of LTB-NS1 Δ63 was assessed by determining its toxicity in vitro and in vivo. Protective capability of LTB-NS1 Δ63 and its-induced antisera was evaluated in the mice challenged with JEV by analyzing mortality and morbidity. Findings: LTB-NS1 Δ63 induced immune responses to a similar level as LTB-NS1, but more robust than NS1 Δ63 alone, particularly in the context of oral immunization of mice. Oral vaccination of LTB-NS1 Δ63 led to a higher survival rate than that of NS1 Δ63 or live-attenuated JEV vaccine SA14À14À2 in the mice receiving lethal JEV challenge. LTB-NS1 Δ63 protein also significantly decreases the morbidity of JEV-infected mice. In addition, passive transfer of LTB-NS1 Δ63 -induced antisera provides a protection against JEV infection in mice. Interpretation: NS1 Δ63 bears JEV NS1 antigenicity. Besides, LTB-NS1 Δ63 could serve as a novel protein-based mucosa vaccine targeting JEV and other flaviviruses.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with E. coli heat labile enterotoxin B subunit

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This study also documented high IL-1b, IL-6, and TNF-α expression levels in PP lymphocytes (PPL) of AmpB-treated mice. These results suggest that the oral administration of the Lip-JENS1 liposome with AmpB represents a potential mucosal vaccine to protect against JEV infection ( Lin et al., 2010 ).…”

Section: Mucosal Vaccine Approaches Used Against Flavivirusmentioning

confidence: 98%

Mucosal Vaccination: A Promising Alternative Against Flaviviruses

Lurı́a-Pérez

Sánchez-Vargas²,

Muñoz-López³

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The Flaviviridae are a family of positive-sense, single-stranded RNA enveloped viruses, and their members belong to a single genus, Flavivirus. Flaviviruses are found in mosquitoes and ticks; they are etiological agents of: dengue fever, Japanese encephalitis, West Nile virus infection, Zika virus infection, tick-borne encephalitis, and yellow fever, among others. Only a few flavivirus vaccines have been licensed for use in humans: yellow fever, dengue fever, Japanese encephalitis, tick-borne encephalitis, and Kyasanur forest disease. However, improvement is necessary in vaccination strategies and in understanding of the immunological mechanisms involved either in the infection or after vaccination. This is especially important in dengue, due to the immunological complexity of its four serotypes, cross-reactive responses, antibody-dependent enhancement, and immunological interference. In this context, mucosal vaccines represent a promising alternative against flaviviruses. Mucosal vaccination has several advantages, as inducing long-term protective immunity in both mucosal and parenteral tissues. It constitutes a friendly route of antigen administration because it is needle-free and allows for a variety of antigen delivery systems. This has promoted the development of several ways to stimulate immunity through the direct administration of antigens (e.g., inactivated virus, attenuated virus, subunits, and DNA), non-replicating vectors (e.g., nanoparticles, liposomes, bacterial ghosts, and defective-replication viral vectors), and replicating vectors (e.g., Salmonella enterica, Lactococcus lactis, Saccharomyces cerevisiae, and viral vectors). Because of these characteristics, mucosal vaccination has been explored for immunoprophylaxis against pathogens that enter the host through mucosae or parenteral areas. It is suitable against flaviviruses because this type of immunization can stimulate the parenteral responses required after bites from flavivirus-infected insects. This review focuses on the advantages of mucosal vaccine candidates against the most relevant flaviviruses in either humans or animals, providing supporting data on the feasibility of this administration route for future clinical trials.

show abstract

“…68 A liposome encapsulating antigens/vaccines, for example, LiposoMAs (liposomal-antigens), liposomes functionalized with distearoyl phosphatidylcholine and cholesterol, and 1,2-dioleoyl-3-trimethylammonium propanebased liposomes, can stimulate specific mucosal responses through oral immunization and are accompanied frequently with a mixed T-helper (Th)1/Th2 immune responses and cellular/humoral immunity. [69][70][71][72][73][74][75] Other synthetic oral vaccines based on liposomes explored include those coated with a bilayer of Tremella and acid-induced alginate, or covalently bound with Ulex europaeus 1 (UEA1) lectin. 76,77 Bilosomes are adjuvants with strengthened stability and protection of peptide antigens as compared with liposomes (Figures 3 and 4).…”

Section: Organic Adjuvant Nps/mpsmentioning

confidence: 99%

Properties and applications of nanoparticle/microparticle conveyors with adjuvant characteristics suitable for oral vaccination

Zhang¹,

Yang²,

Hu³

et al. 2018

IJN

View full text Add to dashboard Cite

Vaccination is one of the most effective approaches in the prevention and control of disease worldwide. Oral vaccination could have wide applications if effective protection cannot be achieved through traditional (eg, parenteral) routes of vaccination. However, oral administration is hampered by the difficulties in transferring vaccines in vivo. This has led to the development of materials such as carriers with potential adjuvant effects. Considering the requirements for selecting adjuvants for oral vaccines as well as the advantages of nanoparticle/microparticle materials as immune effectors and antigen conveyors, synthetic materials could improve the efficiency of oral vaccination. In this review, nanoparticles and microparticles with adjuvant characteristics are described with regard to their potential importance for oral immunization, and some promising and successful modification strategies are summarized.

show abstract

Role of amphotericin B upon enhancement of protective immunity elicited by oral administration with liposome-encapsulated-Japanese encephalitis virus nonstructural protein 1 (NS1) in mice

Cited by 9 publications

References 39 publications

Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with E. coli heat labile enterotoxin B subunit

Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with E. coli heat labile enterotoxin B subunit

Mucosal Vaccination: A Promising Alternative Against Flaviviruses

Properties and applications of nanoparticle/microparticle conveyors with adjuvant characteristics suitable for oral vaccination

Contact Info

Product

Resources

About